Gottlieb ( Spark Therapeutics' Luxturna ) Commissioner Scott Gottlieb has said each year will be critical for the biosimilar market, which makes generic versions of biologics. This feature is part of BioPharma Dive's new feature series, Unblinded, profiling individuals who play central roles in the stories that matter to biotech and pharma. Gottlieb also noted that his successor will be tasked with managing the emergence of gene and cell therapies, as well as the use of anti-competitive tactics by pharmaceutical companies to delay generic rivals to their drugs. Gottlieb oversaw the FDA 's first approval of a gene therapy with FDA , as well as two cell therapies for cancer.
Gottlieb ( Spark Therapeutics' Luxturna ) Commissioner Scott Gottlieb has said each year will be critical for the biosimilar market, which makes generic versions of biologics. Gottlieb also noted that his successor will be tasked with managing the emergence of gene and cell therapies, as well as the use of anti-competitive tactics by pharmaceutical companies to delay generic rivals to their drugs. Gottlieb oversaw the FDA 's first approval of a gene therapy with FDA , as well as two cell therapies for cancer.